Disulfide bonding arrangements in active forms of the somatomedin B domain of human vitronectin

Biochemistry

Volumn 43, Issue 21, 2004, Pages 6519-6534

  Kamikubo, Yuichi ^a   De Guzman, Roberto ^a   Kroon, Gerard ^a   Curriden, Scott ^a   Neels, Jaap G ^a   Churchill, Michael J ^a   Dawson, Philip ^a   Ołdziej, Stanisław ^b   Jagielska, Anna ^b   Scheraga, Harold A ^b   Loskutoff, David J ^a   Dyson, H Jane ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL BONDS; ENZYMES; HYDROPHOBICITY; MOLECULAR STRUCTURE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SOLUTIONS;

BOND ARRANGEMENTS; HIGH AFFINITY BINDING SITES;

BIOCHEMICAL ENGINEERING;

ASPARAGINE; CYANOGEN BROMIDE; CYSTEINE; GLOBULAR PROTEIN; GLYCOPROTEIN; METHIONINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT SOMATOMEDIN B; UROKINASE RECEPTOR; VITRONECTIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONFORMATION; DISULFIDE BOND; HYDROPHOBICITY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR OVERHAUSER EFFECT; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FOLDING; SOMATOMEDIN B DOMAIN;

AMINO ACID SEQUENCE; BINDING SITES; CYSTEINE; DISULFIDES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; SOLUTIONS; SOMATOMEDINS; VITRONECTIN;

EID: 2542633672     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi049647c     Document Type: Article

References (75)

1. Tomasini, B. R., and Mosher, D. F. (1991) in Progress in Hemostasis and Thrombosis (Coller, B. S., Ed.) pp 269-305, Saunders, Philadelphia.
2. Preissner, K. T., and Seiffert, D. (1998) Role of vitronectin and its receptors in haemostasis and vascular remodeling, Thromb. Res. 89, 1-21.
3. Brooks, P. C., Clark, R. A., and Cheresh, D. A. (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis, Science 264, 569-571.
4. Seiffert, D., and Smith, J. W. (1997) The cell adhesion domain in plasma vitronectin is cryptic, J. Biol. Chem. 272, 13705-13710.
5. Smith, J. W., Vestal, D. J., Irwin, S. V., Burke, T. A., and Cheresh, D. A. (1990) Purification and functional characterization of integrin alpha v beta 5. An adhesion receptor for vitronectin, J. Biol. Chem. 265, 11008-11013.
6. Waltz, D. A., and Chapman, H. A. (1994) Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy, J. Biol. Chem. 269, 14746-14750.
7. Wei, Y., Waltz, D. A., Rao, N., Drummond, R. J., Rosenberg, S., and Chapman, H. A. (1994) Identification of the urokinase receptor as an adhesion receptor for vitronectin, J. Biol. Chem. 269, 32380-32388.
8. Deng, G., Curriden, S. A., Wang, S., Rosenberg, S., and Loskutoff, D. J. (1996) Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134, 1563-1571.
9. Sidenius, N., and Blasi, F. (2000) Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin, FEBS Lett. 470, 40-46.
10. Declerck, P. J., De Mol, M., Alessi, M. C., Baudner, S., Paques, E. P., Preissner, K. T., Muller-Berghaus, G., and Collen, D. (1988) Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin), J. Biol. Chem. 263, 15454-15461.
11. Wiman, B., Almquist, A., Sigurdardottir, O., and Lindahl, T. (1988) Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma, FEBS Lett. 242, 125-128.
12. Mimuro, J., and Loskutoff, D. J. (1989) Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin, J. Biol. Chem. 264, 936-939.
13. Salonen, E. M., Vaheri, A., Pollanen, J., Stephens, R., Andreasen, P., Mayer, M., Dano, K., Gailit, J., and Ruoslahti, E. (1989) Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin, J. Biol. Chem. 264, 6339-6343.
14. Gibson, A., Baburaj, K., Day, D. E., Verhamme, I., Shore, J. D., and Peterson, C. B. (1997) The use of fluorescent probes to characterize conformational changes in the interaction between vitronectin and plasminogen activator inhibitor-1, J. Biol. Chem. 272, 5112-5121.
15. Lawrence, D. A., Berkenpas, M. B., Palaniappan, S., and Ginsburg, D. (1994) Localization of vitronectin binding domain in plasminogen activator inhibitor-1, J. Biol. Chem. 269, 15223-15228.
16. Wiman, B., Lindahl, T., and Almqvist, A. (1988) Evidence for a discrete binding protein of plasminogen activator inhibitor in plasma, Thromb. Haemostasis 59, 392-395.
17. Podor, T. J., Peterson, C. B., Lawrence, D. A., Stefansson, S., Shaughnessy, S. G., Foulon, D. M., Butcher, M., and Weitz, J. I. (2000) Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin, J. Biol. Chem. 275, 19788-19794.
18. Wiman, B. (1995) Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease, Thromb. Haemostasis 74, 71-76.
19. Andreasen, P. A., Egelund, R., and Petersen, H. H. (2000) The plasminogen activation system in tumor growth, invasion, and metastasis, Cell Mol. Life Sci. 57, 25-40.
20. Foekens, J. A., Peters, H. A., Look, M. P., Portengen, H., Schmitt, M., Kramer, M. D., Brunner, N., Janicke, F., Meijer-van Gelder, M. E., Henzen-Logmans, S. C., van Putten, W. L., and Klijn, J. G. (2000) The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients, Cancer Res. 60, 636-643.
21. Deng, G., Curriden, S. A., Hu, G., Czekay, R. P., and Loskutoff, D. J. (2001) Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin, J. Cell Physiol. 189, 23-33.
22. Stefansson, S., and Lawrence, D. A. (1996) The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin, Nature 383, 441-443.
23. Kjoller, L., Kanse, S. M., Kirkegaard, T., Rodenburg, K. W., Ronne, E., Goodman, S. L., Preissner, K. T., Ossowski, L., and Andreasen, P. A. (1997) Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation, Exp. Cell Res. 232, 420-429.
24. Czekay, R. P., Aertgeerts, K., Curriden, S. A., and Loskutoff, D. J. (2003) Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins, J. Cell Biol. 160, 781-791.
25. Suzuki, S., Pierschbacher, M. D., Hayman, E. G., Nguyen, K., Ohgren, Y., and Ruoslahti, E. (1984) Domain structure of vitronectin. Alignment of active sites, J. Biol. Chem. 259, 15307-15314.
26. Fryklund, L., and Sievertsson, H. (1978) Primary structure of somatomedin B: a growth hormone-dependent serum factor with protease inhibiting activity, FEBS Lett. 87, 55-60.
27. Ständker, L., Enger, A., Schulz-Knappe, P., Wohn, K. D., Germer, M., Raida, M., Forssmann, W. G., and Preissner, K. T. (1996) Structural and functional characterization of vitronectin-derived RGD-containing peptides from human hemofiltrate, Eur. J. Biochem. 241, 557-563.
28. Izumi, M., Shimo-Oka, T., Morishita, N., Ii, I., and Hayashi, M. (1988) Identification of the collagen-binding domain of vitronectin using monoclonal antibodies, Cell Struct. Funct. 13, 217-225.
29. Akama, T., Yamada, K. M., Seno, N., Matsumoto, I., Kono, I., Kashiwagi, H., Funaki, T., and Hayashi, M. (1986) Immunological characterization of human vitronectin and its binding to glycosaminoglycans, J. Biochem. (Tokyo) 100, 1343-1351.
30. Seiffert, D., and Loskutoff, D. J. (1991) Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin, J. Biol. Chem. 266, 2824-2830.
31. Seiffert, D., Ciambrone, G., Wagner, N. V., Binder, B. R., and Loskutoff, D. J. (1994) The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor, J. Biol. Chem. 269, 2659-2666.
32. Okumura, Y., Kamikubo, Y., Curriden, S. A., Wang, J., Kiwada, T., Futaki, S., Kitagawa, K., and Loskutoff, D. J. (2002) Kinetic analysis of the interaction between vitronectin and the urokinase receptor, J. Biol. Chem. 277, 9395-9404.
33. Philips, M., Johnsen, H., and Thorsen, S. (2000) Characterization of a complex between active plasminogen activator inhibitor-1 and N-terminal fragments of vitronectin from human placenta, Fibrinolysis Proteolysis 14, 22-34.
34. Kamikubo, Y., Okumura, Y., and Loskutoff, D. J. (2002) Identification of the disulfide bonds in the recombinant somatomedin B domain of human vitronectin, J. Biol. Chem. 277, 27109-27119.
35. Deng, G., Royle, G., Wang, S., Crain, K., and Loskutoff, D. J. (1996) Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin, J. Biol. Chem. 271, 12716-12723.
36. Deng, G., Royle, G., Seiffert, D., and Loskutoff, D. J. (1995) The PAI-1/vitronectin interaction: two cats in a bag? Thromb. Haemostasis 74, 66-70.
37. Zhou, A., Huntington, J. A., Pannu, N. S., Carrell, R. W., and Read, R. J. (2003) How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration, Nat. Struct. Biol. 10, 541-544.
38. Royle, G., Deng, G., Seiffert, D., and Loskutoff, D. J. (2001) A method for defining binding sites involved in protein-protein interactions: analysis of the binding of plasminogen activator inhibitor 1 to the somatomedin domain of vitronectin, Anal. Biochem. 296, 245-253.
39. Yatohgo, T., Izumi, M., Kashiwagi, H., and Hayashi, M. (1988) Novel purification of vitronectin from human plasma by heparin affinity chromatography, Cell Struct. Funct. 13, 281-292.
40. Kvassman, J. O., Lawrence, D. A., and Shore, J. D. (1995) The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into beta-sheet A, J. Biol. Chem. 270, 27942-27947.
41. Schnölzer, M., Alewood, P., Jones, A., Alewood, D., and Kent, S. B. H. (1992) In situ neutralization in Boc-chemistry solid-phase peptide synthesis. Rapid, high yield assembly of difficult sequences, Int. J. Pept. Protein Res. 40, 180-193.
42. Jenne, D., and Stanley, K. K. (1985) Molecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion, EMBO J. 4, 3153-3157.
43. Derua, R., Gustafson, K. R., and Pannell, L. K. (1996) Analysis of the disulfide linkage pattern in circulin A and B, HIV-inhibitory macrocyclic peptides, Biochem. Biophys. Res. Commun. 228, 632-638.
44. Delaglio, F., Grzesiek, S., Vuister, G. W., Guang, Z., Pfeifer, J., and Bax, A. (1995) NMRPipe: a multidimensional spectral processing system based on UNIX pipes, J. Biomol. NMR 6, 277-293.
45. Johnson, B. A., and Blevins, R. A. (1994) NMRView: A computer program for the visualization and analysis of NMR data, J. Biomol. NMR 4, 604-613.
46. Bax, A., Vuister, G. W., Grzesiek, S., Delaglio, F., Wang, A. C., Tschudin, R., and Zhu, G. (1994) Measurement of homo- and heteronuclear J-couplings from quantitative J correlation, Methods Enzymol. 239, 79-105.
47. 13C chemical-shift data, J. Biomol. NMR 4, 171-180.
48. Wishart, D. S., and Nip, A. M. (1998) Protein chemical shift analysis: a practical guide, Biochem. Cell Biol. 76, 153-163.
49. Wüthrich, K. (1986) NMR of Proteins and Nucleic Acids, John Wiley and Sons, New York.
50. Güntert, P., Mumenthaler, C., and Wüthrich, K. (1997) Torsion angle dynamics for NMR structure calculation with the new program DYANA, J. Mol. Biol. 273, 283-298.
51. Case, D. A., Pearlman, D. A., Caldwell, J. W., Cheatham, T. E., III, Wang, J., Ross, W. S., Simmerling, C. L., Darden, T. A., Merz, K. M., Stanton, R. V., Cheng, A. L., Vincent, J. J., Crowley, M., Tsui, V., Gohlke, H., Radmer, R. J., Duan, Y., Pitera, J., Massova, I., Seibel, G. L., Singh, U. C., Weiner, P. K., and Kollman, P. A. (2002) AMBER 7, University of California, San Francisco.
52. Cheatham, T. E., III, Cieplak, P., and Kollman, P. A. (1999) A modified version of the Cornell et al. force field with improved sugar pucker phases and helical repeat, J. Biomol. Struct. Dyn. 16, 845-862.
53. Constanciel, R., and Contreras, R. (1984) Self-consistent field-theory of solvent effect representation by continuum models - introduction of desolvation contribution, Theor. Chim. Acta 65, 1-11.
54. Tsui, V., and Case, D. A. (2000) Molecular simulations of nucleic acids using a generalized Born solvation model, J. Am. Chem. Soc. 122, 2489-2498.
55. Tsui, V., and Case, D. A. (2000) Theory and applications of the generalized born solvation model in macromolecular simulations, Biopolymers 56, 275-291.
56. Xia, B., Tsui, V., Case, D. A., Dyson, H. J., and Wright, P. E. (2002) Comparison of solution structures refined by molecular dynamics simulation in a vacuum, with a generalized Born model and with explicit water, J. Biomol. NMR 22, 317-331.
57. Laskowski, R. A., Rullmann, J. A. C., MacArthur, M. W., Kaptein, R., and Thornton, J. M. (1996) AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR, J. Biomol. NMR 8, 477-486.
58. Hutchinson, E. G., and Thornton, J. M. (1996) PROMOTIF-A program to identify and analyze structural motifs in proteins, Protein Sci. 5, 212-220.
59. Koradi, R., Billeter, M., and Wüthrich, K. (1996) MOLMOL: A program for display and analysis of macromolecular structures, J. Mol. Graphics 14, 51-55.
60. Nicholls, A., Sharp, K. A., and Honig, B. (1991) Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons, Proteins 11, 281-296.
61. Liwo, A., Arlukowicz, P., Czaplewski, C., Oldziej, S., Pillardy, J., and Scheraga, H. A. (2002) A method for optimizing potential-energy functions by a hierarchical design of the potential-energy landscape: application to the UNRES force field, Proc. Natl. Acad. Sci. U.S.A. 99, 1937-1942.
62. Lee, J., Scheraga, H. A., and Rackovsky, S. (1997) New optimization method for conformational energy calculations on polypeptides: Conformational space annealing, J. Comput. Chem. 18, 1222-1232.
63. Späth, H. (1980) Cluster Analysis Algorithms, Halsted Press, New York.
64. Kazmierkiewicz, R., Liwo, A., and Scheraga, H. A. (2003) Addition of side chains to a known backbone with defined side-chain centroids, Biophys. Chem. 100, 261-280.
65. Jorgensen, W. L., Chandrasekhar, J., Madura, J., Impey, R. W., and Klein, M. L. (1983) Comparison of simple potential functions for simulating liquid water, J. Chem. Phys. 79, 926-935.
66. Braun, W., and Go, N. (1985) Calculation of protein conformations by proton-proton distance constraints. A new efficient algorithm, J. Mol. Biol. 186, 611-626.
67. Weiser, J., Shenkin, P. S., and Still, W. C. (1999) Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO), J. Comput. Chem. 20, 217-230.
68. Pascual, J., Martinez-Yamout, M., Dyson, H. J., and Wright, P. E. (2000) Structure of the PHD zinc finger from human Williams-Beuren syndrome transcription factor, J. Mol. Biol. 304, 723-729.
69. Duggan, B. M., Legge, G. B., Dyson, H. J., and Wright, P. E. (2001) SANE (Structure assisted NOE evaluation): an automated model-based approach for NOE assignment, J. Biomol. NMR 19, 321-329.
70. Shore, J. D., Day, D. E., Francis-Chmura, A. M., Verhamme, I., Kvassman, J., Lawrence, D. A., and Ginsburg, D. (1995) A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism, J. Biol. Chem. 270, 5395-5398.
71. Wind, T., Hansen, M., Jensen, J. K., and Andreasen, P. A. (2002) The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment, Biol. Chem. 383, 21-36.
72. Sharp, A. M., Stein, P. E., Pannu, N. S., Carrell, R. W., Berkenpas, M. B., Ginsburg, D., Lawrence, D. A., and Read, R. J. (1999) The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion, Structure 7, 111-118.
73. Sui, G. C., and Wiman, B. (1998) Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule, Biochem. J. 331 (Pt 2), 409-415.
74. Jensen, J. K., Wind, T., and Andreasen, P. A. (2002) The vitronectin binding area of plasminogen activator inhibitor-1, mapped by mutagenesis and protection against an inactivating organochemical ligand, FEBS Lett. 521, 91-94.
75. Arroyo, D. P., Schroeck, F., Sinner, E. K., Muehlenweg, B., Twellmeyer, J., Sperl, S., Wilhelm, O. G., Schmitt, M., and Magdolen, V. (2002) Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin, Eur. J. Biochem. 269, 184-192.